论文部分内容阅读
目的探讨羟乙基淀粉130/0.4用于中度低白蛋白血症胃癌患者术后胶体治疗的安全性。方法选择术后血清白蛋白在3.0g/dl至2.5g/dl的胃癌患者65例,分成羟乙基淀粉130/0.4(HES)组和20%人血白蛋白(HA)组,比较两组在白蛋白,凝血功能和肾功能,手术并发症及胶体治疗费用上的差异。结果两组患在白蛋白水平,凝血功能、肾功能,术后并发症上无统计学差异,胶体治疗费用有统计学差异。结论羟乙基淀粉130/0.4能安全有效的应用于中度低白蛋白血症胃癌患者术后的胶体治疗。
Objective To investigate the safety of hydroxyethyl starch 130/0.4 for the treatment of colloids in patients with moderate hypoalbuminemia and gastric cancer. Methods Sixty-five patients with gastric cancer with serum albumin ranging from 3.0g/dl to 2.5g/dl were selected and divided into hydroxyethyl starch 130/0.4 (HES) group and 20% human serum albumin (HA) group. Differences in Albumin, Blood Coagulation and Renal Function, Surgical Complications and Colloidal Treatment Costs. Results There was no statistical difference in albumin level, coagulation function, renal function, and postoperative complications between the two groups. The cost of colloidal therapy was statistically different. Conclusion Hydroxyethyl starch 130/0.4 can be used safely and effectively in the treatment of postoperative colloids in patients with moderate hypoalbuminemia and gastric cancer.